SurModics Inc Cash Flow Conversion Efficiency
SurModics Inc cash flow conversion efficiency. Based on the latest financial reports, SurModics Inc (SRDX) has a cash flow conversion efficiency ratio of 0.013x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.41 Million) by net assets ($111.31 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of SurModics Inc (1998–2024)
Cash flow conversion efficiency of SurModics Inc from 1998 to 2024. This chart illustrates how SurModics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View SurModics Inc (SRDX) share price today for real-time trading data and today's change.
SurModics Inc Cash Flow Conversion Ratio Explained
SurModics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
SurModics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SurModics Inc ranked by their cash flow conversion efficiency. Also see SurModics Inc market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Qian Jiang Water Resources Development Co Ltd
SHG:600283
|
0.031x |
|
Alpha Tau Medical Ltd
NASDAQ:DRTS
|
0.000x |
|
Grid Dynamics Holdings Inc
NASDAQ:GDYN
|
0.012x |
|
GMR Solutions Inc.
NYSE:GMRS
|
0.605x |
|
MarineMax Inc
NYSE:HZO
|
0.018x |
|
CJ ENM CO. Ltd
KQ:035760
|
0.103x |
|
Guangdong Insight Brand Marketing Group Co Ltd
SHE:300781
|
0.006x |
|
Rogers Sugar Inc.
TO:RSI
|
0.099x |
Annual Cash Flow Conversion Efficiency for SurModics Inc (1998–2024)
The table below shows the annual cash flow conversion efficiency of SurModics Inc from 1998 to 2024. Review SRDX FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-09-30 | $118.90 Million | $248.00K | 0.002x | -97.62% |
| 2023-09-30 | $119.91 Million | $10.51 Million | 0.088x | +155.18% |
| 2022-09-30 | $108.39 Million | $-17.22 Million | -0.159x | -244.64% |
| 2021-09-30 | $140.09 Million | $15.39 Million | 0.110x | +2.76% |
| 2020-09-30 | $131.06 Million | $14.01 Million | 0.107x | +62.94% |
| 2019-09-30 | $122.52 Million | $8.04 Million | 0.066x | -79.07% |
| 2018-09-30 | $108.61 Million | $34.05 Million | 0.314x | +148.89% |
| 2017-09-30 | $111.56 Million | $14.05 Million | 0.126x | -46.52% |
| 2016-09-30 | $106.83 Million | $25.17 Million | 0.236x | +46.43% |
| 2015-09-30 | $93.37 Million | $15.02 Million | 0.161x | -12.64% |
| 2014-09-30 | $98.75 Million | $18.18 Million | 0.184x | -2.20% |
| 2013-09-30 | $93.82 Million | $17.66 Million | 0.188x | +10.66% |
| 2012-09-30 | $94.69 Million | $16.11 Million | 0.170x | +23.92% |
| 2011-09-30 | $145.34 Million | $19.95 Million | 0.137x | -3.70% |
| 2010-09-30 | $154.36 Million | $22.01 Million | 0.143x | -21.53% |
| 2009-09-30 | $172.37 Million | $31.32 Million | 0.182x | -35.29% |
| 2008-09-30 | $141.81 Million | $39.82 Million | 0.281x | -27.50% |
| 2007-09-30 | $130.92 Million | $50.71 Million | 0.387x | +59.43% |
| 2006-09-30 | $145.20 Million | $35.28 Million | 0.243x | +8.22% |
| 2005-09-30 | $115.58 Million | $25.95 Million | 0.225x | +8.85% |
| 2004-09-30 | $94.50 Million | $19.49 Million | 0.206x | -7.77% |
| 2003-09-30 | $86.11 Million | $19.26 Million | 0.224x | +9.36% |
| 2002-09-30 | $70.00 Million | $14.31 Million | 0.204x | +45.82% |
| 2001-09-30 | $55.70 Million | $7.81 Million | 0.140x | -8.18% |
| 2000-09-30 | $48.30 Million | $7.38 Million | 0.153x | +3.09% |
| 1999-09-30 | $29.70 Million | $4.40 Million | 0.148x | +60.14% |
| 1998-09-30 | $22.70 Million | $2.10 Million | 0.093x | -- |
About SurModics Inc
Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision o… Read more